Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.

Crohn’s disease, disease burden may weaken vedolizumab efficacy in IBD patients

29 Oct 2018

Vedolizumab is safe and effective in the treatment of inflammatory bowel disease (IBD) patients, according to a study. However, Crohn’s disease (CD) and a more severe disease appear to impair both short- and long-term effectiveness of the drug.

Researchers looked at 508 patients (median age 42 years; 54.8 percent female; 50.9 percent had CD) who received 1 induction dose of vedolizumab, with a median follow-up of 10 months. Effectiveness was measured using the Harvey-Bradshaw index (HBI) in CD and the Partial Mayo Score (PMS) in ulcerative colitis (UC).  Responses to treatment in the short term (week 14) and the long-term were evaluated.

Overall, 46.8 percent of patients achieved remission while 15.7 percent had clinical response at week 14. CD, previous surgery, higher C-reactive protein (CRP) concentration and greater disease severity at baseline emerged as significant predictors of impaired response.

Vedolizumab discontinuation rate was 37 percent per patient-year of follow-up (27.6 percent in UC; 45.3 percent in CD; p<0.01). Factors significantly associated with lower treatment durability included CD, anaemia at baseline, steroids during induction and CRP concentration.

Adverse events occurred in 7.1 percent of patients overall. The most commonly reported were infections such as those of the sinopulmonary and gastrointestinal tracts.

Additional clinical trials are needed to place vedolizumab in the therapeutic algorithm of IBD patients, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 10 Jul 2018
A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Audrey Abella, 21 Dec 2018
Use of a single course of the intravenous iron preparation ferumoxytol may lead to sustained improvements in patient-reported outcomes (PROs) of individuals with iron deficiency anaemia (IDA) who had inadequate response to oral iron therapy, according to data presented at ASH 2018.
Saras Ramiya, 23 Oct 2018
The Malaysian Pharmacy Students’ Association (MyPSA) has successfully organized the 13th National Gathering of Pharmacy Students (NoGAPS) in September.